Kevin Feeley, Chief Financial Officer of GeneDx Holdings Corp., filed a Form 4 on September 3, 2026, disclosing transactions dated September 1, 2026, involving the vesting of restricted stock units and a related share sale to cover tax withholding obligations.
Key Highlights
- RSU settlement: 717 shares of Class A Common Stock were acquired by Feeley at $0 through the vesting and settlement of restricted stock units on September 1, 2026.
- Tax-related sale: 372 shares were sold at a weighted average price of $83.839 per share, in multiple transactions ranging from $83.71 to $83.84, to satisfy tax withholding obligations via a "sell to cover" transaction.
- Post-transaction ownership: Following these transactions, Feeley directly owned 40,299 shares of Class A Common Stock.
- Additional holdings: Feeley also held RSUs representing contingent rights to receive up to an aggregate 81,326 shares and options to purchase up to an aggregate 25,906 shares of Class A Common Stock, vesting according to their respective terms.
- RSU vesting schedule: The RSUs vest at 6.25% of the total award quarterly, with the first tranche having vested on December 1, 2022, subject to continued service.
GeneDx Holdings CFO Kevin Feeley: RSU Vesting and Sell-to-Cover Details
According to the filing, Kevin Feeley, identified as Chief Financial Officer of GeneDx Holdings Corp. (NASDAQ:WGS), reported two transactions in Class A Common Stock on September 1, 2026. The first was the acquisition of 717 shares at $0 per share, reflecting the settlement of restricted stock units. As the filing explains, each RSU "represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration."
The second transaction was the sale of 372 shares at a weighted average price of $83.839, with individual sales occurring at prices ranging from $83.71 to $83.84 per share. The filing states that this sale "represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs" and "does not represent a discretionary transaction by the Reporting Person." Feeley directly owned 40,299 shares of Class A Common Stock following these transactions, as reported in the filing.
The filing further disclosed that, in addition to the 40,299 directly held shares, Feeley held RSUs representing contingent rights to receive up to an aggregate 81,326 shares and options to purchase up to an aggregate 25,906 shares of Class A Common Stock. The RSU award vests at 6.25% quarterly, with the initial tranche having vested on December 1, 2022, contingent on continued service. The form was signed by Bridget Brown as Attorney-in-Fact and filed on September 3, 2026.
What Was Disclosed
The Form 4 filed by GeneDx Holdings Corp. CFO Kevin Feeley reported the September 1, 2026, settlement of 717 RSUs into Class A Common Stock and the immediate sale of 372 shares at a weighted average of $83.839 to cover tax withholding, leaving him with 40,299 directly owned shares.




Please wait processing your request...